Back ground: Alopecia areata is a recurrent, non-scaring type of hair loss considered to be an autoimmune process. Though its etiopathogenesis is not fully understood, many therapeutic options have been used by dermatologists, but none are curative or preventive. Prostaglandins analogues which are used to treat glaucoma. Increase in eye lash number, thickness and pigmentation have been reported as side effect. Methods: This cross sectional case control study was conducted on thirty seven Egyptian patients with alopecia areata including 15 females and 22 males with age ranging from 18 to 45 years old. Eight healthy Egyptian volunteers who had no systemic or dermatological diseases of matching age, sex and BMI served as control. The assessment was performed according to SALT score. Results: There was statistically highly significant difference between the two groups regarding the mean value of PGD2 in tissue in AA patients. It was significantly lower than in control group (p < 0.001). The mean value of PGD2 in serum in AA patients was significantly lower than in control group (p< 0.05). Conclusion: Prostaglandin D2 exhibits a strong role in etiology of alopecia areata and significantly was elevated in serum and tissue of alopecia areata patients.
Introduction
Alopecia areata is classified as an autoimmune disorder, characterized by one or more circumscribed, totally bald, smooth, patches appear suddenly, most often on the scalp. Alopecia areata is also called ISSN: 2536-9474 (Print) Original article / FYMJ ISSN: 2536-9482 (Online) Fayoum University Medical Journal Soliman et al., 2019,4(1) , 77-85
Page 78 autoimmune alopecia. This disease affects males and females at any age. It starts in childhood in about 50%, and before the age of 40 years in 80% (Lattouf C et al., 2015) .
Alopecia Areata is inflammatory disease that involves the hair follicle and sometimes the nails. This inflammation is caused by a T-cell mediated autoimmune mechanism occurring in genetically predisposed individuals (Craiglow BG et al., 2014) . The 
Subjects and Methods
It was a prospective case-control study. 
Results
There was a statistically significant difference between Tissue PGD2 & Serum PGD2 in cases than control with p value ˂ 0.01. Course was progressive in 26 patients (70%), stationary in 4 patients (10%) and with exacerbations and remissions in 7 patients (20%) (Fig 2) . Fig 3) . 1) (Fig 4) . 
Figure 3. Comparison between AA patients regarding associated

Discussion
This study is the first study that talks in , 1996) . PTGDS was confirmed to be elevated in bald scalp by mRNA, protein and also its enzymatic product, PGD2. Importantly, its increase was confirmed by mass spectrometry which has been shown to be superior to conventional ELISA based methods which use marginally specific antibodies for the selective identification of individual prostaglandin species (Bell et al., 2003) . So confirmed the correlation between PGD2 and alopecia.
There was a highly statistically significant difference between between AA patients and control group regarding PG D2 serum and tissue levels, there was a highly increase in PG D2 levels in both serum and tissue in AA patients with p value ˂ 0.01.
These results suggest that PG D2 has a strong role in Alopecia areata pathogenesis. This is the first study to prove the relation between PG D2 and Alopecia areata
Conclusion and recommendations
Prostaglandin D2 exhibits a strong role in AA with its inflammatory effect. It was highly expressed in Alopecia areata patients serum& tissue levels than healthy individuals.
We suggest that prostaglandin analogue could become a potential therapeutic target for treating AA in the future with its strong role in Alopecia areata, and we need further clinical study to asses which prostaglandin analogues will be highly curable with alopecia areata. University, for his precious advices and great help during the preparation of this work. I was blessed to get their support.
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